Infantile Takayasu: clinical features and long-term outcome
Authors' conclusion
Compared with other reported series on older children, infants with TAK have more severe disease and were more likely to receive biologic agents, develop complications, and require invasive interventions.
Study context
- Population
- Children diagnosed with TAK at age <5 years meeting EULAR/PReS 2008 and 1990 ACR/EULAR criteria, six rheumatology centres50% female
- Participants
- 12 children
- Outcome
- Demographic and clinical characteristics of infantile TAK
Methodological detailsinternational, multicentre, case series
- International
- Multicentre
- Case series
Main finding
As reported in the abstract
Median age of symptom onset
11 months
Diagnostic delay
4 months
Invasive procedures required
58%
Observational data: associations, not effects.
Further findings
Complete remission by medication
- Infliximab (highest among biologics; half of patients received biologics)
- 40%
- CYC
- 40%
- MTX
- 38%
Safety
Complications
- Cardiac
- 50%
- Stroke
- 42%
- Serious infections
- 33%
- Deaths
- 0
Original publication
Infantile Takayasu: clinical features and long-term outcome. Rheumatology (Oxford). Published 10 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →